Virbac share rebounds by 1.5% this morning
The veterinary laboratory from Carros is finding its footing again on Monday, ten days after a difficult session following its half-yearly results. The rebound occurs in a quasi-stable SBF 120, which makes Virbac's progress particularly visible within the index.
A technical rebound below three moving averages still distant
The Virbac share gains 1.48% to 308 € during the session, after closing the previous session on Friday at 303.50 €. This rebound takes place in a still tense technical context: the security remains below its 20-day moving average at 312.65 € (gap of -1.49%), its 50-day moving average at 326.21 € (-5.58%) and its 200-day moving average at 345.65 € (-10.89%), three levels that form as many upside resistance levels. The RSI at 36 reflects a configuration still close to oversold, without crossing the threshold, which leaves room for a rebound but does not signal a confirmed trend reversal.
The support level at 302 € remains the reference low to monitor, while resistance at 332.50 € represents the next notable obstacle if the momentum continues. Over one month, the security is still down 4.64%, and over three months the loss exceeds 9%. The one billion euro share buyback program announced in June 2026 constitutes a contextual element likely to support the price in the medium term.
Solid half-yearly results but a security still under pressure since September
Monday's rebound comes after a difficult session on September 18, during which the security dropped 5.5%, worst performer of the SBF 120, despite the publication of half-yearly results deemed solid. Organic growth for the first half of 2026 had reached 7.4%, and management had confirmed its annual targets by placing itself at the upper end of the growth range, with revenue targeted at approximately 1,574 million euros for the full fiscal year, according to guidance communicated when publishing results on July 20, 2026. Before this September episode, the security had already broken its support at 314 € in early September in a context of pressure on the Paris market. Today's session, which places Virbac among the strongest gainers of the SBF 120, marks a lull, but the security remains more than 10% below its 200-day moving average and maintains negative year-to-date performance of -1.75%.
Two funds moreover maintain declared net short positions on the security, a level that testifies to residual caution from certain institutional investors, without one being able to infer an affirmed downward trend. The support at 302 € remains the short-term reference not to be lost.
